Sabrina Hadam

Sabrina Hadam

Auto-generated profile, based on publicly available information

Sabrina Hadam

Department of Dermatology, Venereology and Allergology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 July 2017 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
NDNadine Döge
Nadine Döge
AAAraks Avetisyan
Araks Avetisyan
SHSabrina Hadam
Sabrina Hadam
EPEva Katharina Barbosa Pfannes
Eva Katharina Barbosa Pfannes
Fiorenza RancanFiorenza Rancan
Fiorenza Rancan
AVAnnika Vogt
Annika Vogt

Verified
Journal Article
Open access
PDF file
PVPierre Volz
Pierre Volz
ABAlexander Boreham
Alexander Boreham
AWAlexander Wolf
Alexander Wolf
TKTai-Yang Kim
Tai-Yang Kim
JBJens Balke
Jens Balke
UAUlrike Alexiev
Ulrike Alexiev
We report here on the application of laser-based single molecule total internal reflection fluorescence microscopy (TIRFM) to study the penetration of molecules through the skin. Penetration of topically applied drug molecules is often observed to be limited by the size of the respective drug. However, the molecular mechanisms which govern the penetration of molecules through the outermost layer of the skin are still largely unknown. As a model compound we have chosen a larger amphiphilic molecule (fluorescent dye ATTO-Oxa12) with a molecular weight >700 Da that was applied to excised human skin. ATTO-Oxa12 penetrated through the stratum corneum (SC) into the viable epidermis as revealed by TIRFM of cryosections. Single particle tracking of ATTO-Oxa12 within SC sheets obtained by tape stripping allowed us to gain information on the localization as well as the lateral diffusion dynamics of these molecules. ATTO-Oxa12 appeared to be highly confined in the SC lipid region between (intercellular space) or close to the envelope of the corneocytes. Three main distinct confinement sizes of 52 ± 6, 118 ± 4, and 205 ± 5 nm were determined. We conclude that for this amphiphilic model compound several pathways through the skin exist.

3 September 2013 in Skin Research and Technology
Verified
Journal Article
Closed access
PDF file
Fiorenza RancanFiorenza Rancan
Fiorenza Rancan
BNB. Nazemi
B. Nazemi
SRS. Rautenberg
S. Rautenberg
MRM. Ryll
M. Ryll
SHS. Hadam
S. Hadam
Martina MeinkeMartina Meinke
Martina Meinke

29 December 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
KRKeerthana Rajes
Keerthana Rajes
KWKarolina A. Walker
Karolina A. Walker
SHSabrina Hadam
Sabrina Hadam
FZFatemeh Zabihi
Fatemeh Zabihi
Fiorenza RancanFiorenza Rancan
Fiorenza Rancan
RHRainer Haag
Rainer Haag
A synthetic route for redox-sensitive and non-sensitive core multi-shell (CMS) carriers with sizes below 20 nm and narrow molecular weight distributions was established. Cyclic voltammetric measurements were conducted characterizing the redox potentials of reduction-sensitive CMS while showcasing its reducibility through glutathione and tris(2-carboxyethyl)-phosphine as a proof of concept. Measurements of reduction-initiated release of the model dye Nile red by time-dependent fluorescence spectroscopy showed a pronounced release for the redox-sensitive CMS nanocarrier (up to 90% within 24 h) while the non-sensitive nanocarriers showed no release in PBS. Penetration experiments using ex vivo human skin showed that the redox-sensitive CMS nanocarrier could deliver higher percentages of the loaded macrocyclic dye meso-tetra (m-hydroxyphenyl) porphyrin (mTHPP) to the skin as compared to the non-sensitive CMS nanocarrier. Encapsulation experiments showed that these CMS nanocarriers can encapsulate dyes or drugs with different molecular weights and hydrophobicity. A drug content of 1 to 6 wt% was achieved for the anti-inflammatory drugs dexamethasone and rapamycin as well as fluorescent dyes such as Nile red and porphyrins. These results show that redox-initiated drug release is a promising strategy to improve the topical drug delivery of macrolide drugs.

3 July 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Fiorenza RancanFiorenza Rancan
Fiorenza Rancan
JJJana Jurisch
Jana Jurisch
SHSabrina Hadam
Sabrina Hadam
AVAnnika Vogt
Annika Vogt
UBUlrike Blume-Peytavi
Ulrike Blume-Peytavi
CSChristoph Schaudinn
Christoph Schaudinn
Bacterial infections are a constant challenge in the management of acute and chronic wounds. Chronic wounds, such as diabetic foot ulcers, have increased significantly in the last few years due to the rise of an aging population. A better understanding of the infectious pathophysiological mechanisms is urgently needed along with new options for the treatment of wound infections and wound-healing disorders. New advances in the preparation of biocompatible dressing materials that can be loaded with antimicrobial drugs may improve the topical treatment of infected wounds. In this study, we investigated the antimicrobial activity of polyvinylpyrrolidone (PVP) foils loaded with ciprofloxacin (Cipro-foils) in the presence of acetic acid as a co-solvent. We used ex vivo human wounds that were infected with two bacterial strains: methicillin-resistant Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa (PAO1). The effectiveness of the treatment was demonstrated by the quantification of the living bacteria extracted from the wound and the detection of released immunological mediators in skin extracts and in the skin culture media. We found that Cipro-foils effectively treated the infection with both PAO1 and MRSA. Other than PAO1, MRSA had no lytic activity toward skin proteins. MRSA infections increased cytokines’ expression and release. Interestingly, treatment with Cipro-foils could partially counteract these effects.